Episode
Long-term efficacy and safety of betibeglogene autotemcel for β-thalassemia
- Podcast
- Blood Podcast
- Published
- May 7, 2026
- Duration seconds
- 784
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/b9b05532
Actions
POST https://stenobird.com/v1/public/podcasts/blood-podcast-664776/episodes/long-term-efficacy-and-safety-of-betibeglogene-autotemcel-for-thalassemia/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-podcast-664776/long-term-efficacy-and-safety-of-betibeglogene-autotemcel-for-thalassemia.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this week's episode, Blood editor Dr. Laura Michaelis interviews Dr. Alexis Thompson, former ASH president, on her latest article published in Blood . Dr. Thompson discusses " Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia ." She explains transfusion-dependent β-thalassemia (TDT) requires rigorous, lifelong transfusion therapy and iron chelation to manage iron overload. Dr. Kwiatkowski and colleagues discuss the long-term efficacy and safety of this gene therapy in 63 patients with TDT, documenting sustained transfusion independence for up to 10 years and a safety profile consistent with that of myeloablative autologous transplantation.